HOME > TRENDS
TRENDS
-
Multiple Authorized Generics Get Approval towards June Listing as Pharmas See Opportunities
February 17, 2016
-
Japan Drug Makers Foresee 6% Sales Growth in FY2015: Jiho Tally
February 15, 2016
-
17,800 Hep C Patients Prescribed Sovaldi in 6 Months; Clinical Benefits Out of Consideration in New Re-Pricing Rule
January 27, 2016
-
Global Pharmas Mull Excluding Japan from In-Licensing Deals on Annual Revision Fears, Softer Yen
January 26, 2016
-
Takeda’s Exit from Diabetes Research a Symbolic Move under Weber Leadership
January 20, 2016
-
Teva JV Deal Marks Turning Point in Takeda’s Japanese Business
January 6, 2016
-
“Huge Seller” Re-Pricing Targeting Hep C Drugs Will Dampen Innovative Market
December 9, 2015
-
Peak Sales Forecast for New Drugs Listed in 2015 Exceeded 840 Billion Yen with Big Contribution from Hep C Treatments
December 7, 2015
-
AG Shares Reach 50-60% in 1 Year; Confidence in Quality Encourages Dominance Even without Market Lead
November 30, 2015
-
Full-Year Forecasts for Domestic Market Down vs Previous Year; Major Makers Struggling Even in Year without NHI Price Revision
November 11, 2015
-
Shift to Specialty - 5: Eisai, Ajinomoto Jump on Specialty Bandwagon to Seek Efficiency in GI Biz
October 30, 2015
-
Drug Makers’ Payments to Medical Institutions Dip for Second Year: Jiho Tally
September 15, 2015
-
Transformation of ARB Market Spurred by AGs, Power Map Changing Fast as Brand-Name Drugs Falter
September 4, 2015
-
Japan Drug Makers See Rising Overseas Sales Ratios in April-June
August 11, 2015
-
IFN-Free Drugs Upending Hepatitis C Market Landscape
July 17, 2015
-
3 Major Japan Makers Shed 1,300 Jobs amid Redundancy Programs
June 30, 2015
-
“80% Generic” Era Would Further Accelerate Contraction of Market for Long-Listed Drugs
June 29, 2015
-
Top-4 Japanese Drug Makers Report Widely Different Financial Results for FY2014
May 22, 2015
-
Will 5,000 Contract Sales Reps Be Just a Way Station for a Higher Goal Beyond?
April 24, 2015
-
Global Drug Sales Rose 8.8% to US$936.5 Billion in 2014: IMS Health
April 3, 2015
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…